{"id":"factor-ix-fix","safety":{"commonSideEffects":[{"rate":null,"effect":"Thrombosis (deep vein thrombosis, pulmonary embolism)"},{"rate":null,"effect":"Inhibitor development (anti-Factor IX antibodies)"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fever"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Factor IX is a serine protease that functions as part of the tenase complex in the intrinsic coagulation cascade. By replacing missing or defective endogenous Factor IX, the drug restores the ability to generate thrombin and form stable fibrin clots. This is essential for patients with Factor IX deficiency (hemophilia B) who otherwise have impaired coagulation and are at risk of spontaneous or excessive bleeding.","oneSentence":"Factor IX is a vitamin K-dependent clotting factor that replaces deficient or dysfunctional Factor IX to restore the intrinsic coagulation pathway and enable normal blood clot formation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:46:40.989Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hemophilia B (Factor IX deficiency) — prevention and treatment of bleeding episodes"},{"name":"Hemophilia B — perioperative management"}]},"trialDetails":[{"nctId":"NCT03569891","phase":"PHASE3","title":"HOPE-B: Trial of AMT-061 in Severe or Moderately Severe Hemophilia B Patients","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2018-06-27","conditions":"Hemophilia B","enrollment":67},{"nctId":"NCT06096051","phase":"","title":"Evaluation of 4-Factor PCC in DOAC-associated Intracranial Hemorrhage","status":"COMPLETED","sponsor":"Methodist Health System","startDate":"2023-06-13","conditions":"Intracranial Hemorrhage","enrollment":76},{"nctId":"NCT06379789","phase":"PHASE1, PHASE2","title":"A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-09-11","conditions":"Hemophilia B","enrollment":130},{"nctId":"NCT01687608","phase":"PHASE1, PHASE2","title":"Open-Label Single Ascending Dose of Adeno-associated Virus Serotype 8 Factor IX Gene Therapy in Adults With Hemophilia B","status":"ACTIVE_NOT_RECRUITING","sponsor":"Baxalta now part of Shire","startDate":"2013-02-11","conditions":"Hemophilia B","enrollment":30},{"nctId":"NCT05568459","phase":"","title":"A Trial That Evaluates Disease Characteristics in Hemophilia B Adult Male Participants Receiving Prophylaxis With Standard of Care Factor IX Protein (FIX) Replacement Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-01-17","conditions":"Hemophilia B","enrollment":11},{"nctId":"NCT03307980","phase":"PHASE2","title":"Long-term Safety and Efficacy Study and Dose-Escalation Substudy of PF 06838435 in Individuals With Hemophilia B","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2017-06-22","conditions":"Hemophilia B","enrollment":21},{"nctId":"NCT06003387","phase":"PHASE3","title":"Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs)","status":"RECRUITING","sponsor":"CSL Behring","startDate":"2024-01-30","conditions":"Hemophilia B","enrollment":35},{"nctId":"NCT07094087","phase":"PHASE3","title":"Efficacy and Safety of 4F-PCC (4-Factor Prothrombin Complex Concentrate) in Adult Patients Undergoing Complex Cardiovascular Surgery With Cardiopulmonary Bypass (CPB)","status":"RECRUITING","sponsor":"CSL Behring","startDate":"2025-09-15","conditions":"Complex Cardiovascular Surgery With Cardiopulmonary Bypass","enrollment":200},{"nctId":"NCT03861273","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Factor IX Gene Therapy With PF-06838435 in Adult Males With Moderately Severe to Severe Hemophilia B","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2019-07-29","conditions":"Hemophilia B","enrollment":51},{"nctId":"NCT06349473","phase":"PHASE1","title":"A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency)","status":"RECRUITING","sponsor":"Equilibra Bioscience LLC","startDate":"2024-05-10","conditions":"Healthy Participants, Hemophilia A, Hemophilia B","enrollment":31},{"nctId":"NCT04590950","phase":"","title":"Dosage and PD Study of Eftrenonacog-alfa","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2019-12-18","conditions":"Severe Haemophilia B","enrollment":15},{"nctId":"NCT05568719","phase":"PHASE3","title":"Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively","status":"RECRUITING","sponsor":"Pfizer","startDate":"2022-12-28","conditions":"Hemophilia A, Hemophilia B","enrollment":173},{"nctId":"NCT07425327","phase":"","title":"Validity and Reliability of the Two-minute Step Test in Hemophilia","status":"NOT_YET_RECRUITING","sponsor":"Hasan Kalyoncu University","startDate":"2026-02-25","conditions":"Hemophilia, Step, Reliability and Validity","enrollment":35},{"nctId":"NCT06008938","phase":"","title":"An Observational Cohort Study to Characterize the Effectiveness and Safety of HEMGENIX® in Patients With Hemophilia B","status":"RECRUITING","sponsor":"CSL Behring","startDate":"2023-06-15","conditions":"Hemophilia B","enrollment":500},{"nctId":"NCT05932914","phase":"","title":"Liver Biopsy Following Gene Therapy For Hemophilia","status":"NOT_YET_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2026-03","conditions":"Hemophilia A, Hemophilia B","enrollment":8},{"nctId":"NCT05145127","phase":"PHASE3","title":"Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors","status":"RECRUITING","sponsor":"Pfizer","startDate":"2021-11-17","conditions":"Hemophilia A, Hemophilia B","enrollment":245},{"nctId":"NCT07080905","phase":"PHASE3","title":"Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B","status":"RECRUITING","sponsor":"CSL Behring","startDate":"2025-07-28","conditions":"Hemophilia B","enrollment":20},{"nctId":"NCT05662319","phase":"PHASE3","title":"A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe Hemophilia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2023-02-01","conditions":"Hemophilia","enrollment":91},{"nctId":"NCT00979238","phase":"PHASE1","title":"Dose-Escalation Study Of A Self Complementary Adeno-Associated Viral Vector For Gene Transfer in Hemophilia B","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2010-02-22","conditions":"Hemophilia B","enrollment":14},{"nctId":"NCT06929260","phase":"PHASE1","title":"A Study to Evaluate the Effect of Ceralasertib on Drug X, Drug Y and Drug Z","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2025-05-21","conditions":"Advanced Solid Tumours","enrollment":1},{"nctId":"NCT04647227","phase":"PHASE4","title":"SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors","status":"RECRUITING","sponsor":"American Thrombosis and Hemostasis Network","startDate":"2021-06-28","conditions":"Hemophilia A With Inhibitor, Hemophilia B With Inhibitor","enrollment":55},{"nctId":"NCT06399289","phase":"PHASE3","title":"Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Chinese Subjects With Hemophilia B Previously Treated With FIX Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"CSL Behring","startDate":"2024-07-28","conditions":"Hemophilia B","enrollment":23},{"nctId":"NCT05568888","phase":"PHASE3","title":"Evaluation of BE1116 in Patients With Traumatic Injury and Acute Major Bleeding to Improve Survival ( TAP Study )","status":"TERMINATED","sponsor":"CSL Behring","startDate":"2023-03-28","conditions":"Traumatic Injury","enrollment":1366},{"nctId":"NCT06700096","phase":"PHASE3","title":"An Open-Label, Comparative Study of the Efficacy, Safety and Pharmacodynamics of Single Dose of ANB-002 in Patients With Hemophilia B","status":"RECRUITING","sponsor":"Biocad","startDate":"2024-11-07","conditions":"Hemophilia B","enrollment":24},{"nctId":"NCT05044845","phase":"","title":"Needs Assessment of Knowledge, Beliefs, and Attitudes of Patients With Hemophilia B About Gene Therapy","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2022-01-18","conditions":"Gene Therapy, Hemophilia B","enrollment":150},{"nctId":"NCT03587116","phase":"PHASE3","title":"A Study to Evaluate Prospective Efficacy and Safety Data of Current FIX Prophylaxis Replacement Therapy in Adult Hemophilia B Subjects (FIX:C≤2%) or Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Subjects (FVIII:C≤1%)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-07-26","conditions":"Hemophilia B, Hemophilia A","enrollment":212},{"nctId":"NCT04244981","phase":"PHASE4","title":"Efficacy of Prothrombin Complex Concentrate Reducing Perioperative Blood Loss in Cardiac Surgery","status":"RECRUITING","sponsor":"SHI Jia","startDate":"2023-10-25","conditions":"Cardiac Surgical Procedures","enrollment":820},{"nctId":"NCT06611436","phase":"PHASE1, PHASE2","title":"BeCoMe-9: A Clinical Study of BE-101 for the Treatment of Adults With Moderately Severe or Severe Hemophilia B","status":"RECRUITING","sponsor":"Be Biopharma","startDate":"2024-12-04","conditions":"Hemophilia B, Hemophilia B, Moderately Severe or Severe","enrollment":24},{"nctId":"NCT03901755","phase":"","title":"An International Study to Evaluate the Real-world Effectiveness and Usage of Alprolix in Patients With Haemophilia B","status":"COMPLETED","sponsor":"Swedish Orphan Biovitrum","startDate":"2019-09-12","conditions":"Hemophilia B","enrollment":151},{"nctId":"NCT04023019","phase":"","title":"Treatment of Hemophilia A Patients With FVIII Inhibitors","status":"RECRUITING","sponsor":"Emory University","startDate":"2020-03-17","conditions":"Hemophilia A","enrollment":120},{"nctId":"NCT06634836","phase":"","title":"Patient Interview Study to Explore the Impact of Gene Therapy in Hemophilia A & B","status":"WITHDRAWN","sponsor":"Pfizer","startDate":"2025-03-17","conditions":"Hemophilia A, Hemophilia B","enrollment":""},{"nctId":"NCT05360706","phase":"","title":"Study of AAV5-hFIX in Severe or Moderately Severe Haemophilia B","status":"ACTIVE_NOT_RECRUITING","sponsor":"CSL Behring","startDate":"2021-03-18","conditions":"Hemophilia B","enrollment":9},{"nctId":"NCT04543383","phase":"PHASE1","title":"A Study to Assess the Reversal of the Anticoagulant Effects of Milvexian by 4-Factor Prothrombin Complex Concentrate (4F-PCC) (Part 1) and Recombinant Human Factor VIIa (rFVIIa) (Part 2) in Healthy Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2020-07-27","conditions":"Healthy","enrollment":52},{"nctId":"NCT05611801","phase":"PHASE3","title":"A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B","status":"RECRUITING","sponsor":"Pfizer","startDate":"2022-12-09","conditions":"Hemophilia A, Hemophilia B","enrollment":100},{"nctId":"NCT07101224","phase":"","title":"Data Registry in Chinese Hemophilia A and B Patients","status":"COMPLETED","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2017-05-07","conditions":"Hemophilia A, Hemophilia B","enrollment":200},{"nctId":"NCT06144112","phase":"PHASE4","title":"Fibrinogen Concentrates Versus Cryoprecipitate in Liver Transplant Surgery","status":"NOT_YET_RECRUITING","sponsor":"Konkuk University Medical Center","startDate":"2025-09-01","conditions":"Liver Diseases","enrollment":92},{"nctId":"NCT05962398","phase":"","title":"Long-term Follow-up Study of Male Adults With Hemophilia B Previously Treated With Etranacogene Dezaparvovec (CSL222)","status":"ENROLLING_BY_INVITATION","sponsor":"CSL Behring","startDate":"2023-08-30","conditions":"Hemophilia B","enrollment":56},{"nctId":"NCT01154231","phase":"","title":"BeneFIX Drug Use Results Survey [All-Case Surveillance]","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-10-29","conditions":"Hemophilia B","enrollment":314},{"nctId":"NCT02740413","phase":"","title":"Treatment Patterns And Outcomes In Patients Treated With Benefix Or Refacto/Refacto AF - A Swedish Cohort Study","status":"COMPLETED","sponsor":"Pfizer","startDate":"2016-01-11","conditions":"Hemophilia A, Hemophilia B","enrollment":86},{"nctId":"NCT05203679","phase":"PHASE2, PHASE3","title":"Evaluation of the Safety and Efficacy of Hemophilia B Gene Therapy Drug","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Xinzhi BioMed Co., Ltd.","startDate":"2021-12-30","conditions":"Hemophilia B","enrollment":32},{"nctId":"NCT06120582","phase":"PHASE1, PHASE2","title":"Study of the Safety, Pharmacodynamics and Efficacy of ANB-002 in Patients With Hemophilia B (SAFRAN)","status":"RECRUITING","sponsor":"Biocad","startDate":"2023-05-02","conditions":"Hemophilia B","enrollment":28},{"nctId":"NCT03938792","phase":"PHASE3","title":"Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B","status":"COMPLETED","sponsor":"Pfizer","startDate":"2020-03-09","conditions":"Hemophilia A, Hemophilia B","enrollment":189},{"nctId":"NCT05437211","phase":"NA","title":"A Proof-of-concept Study to Reduce Treatment Burden in Haemophilia Participants Receiving Factor VIII and Factor IX Infusions","status":"COMPLETED","sponsor":"Takeda","startDate":"2023-06-23","conditions":"Hemophilia","enrollment":24},{"nctId":"NCT03341156","phase":"PHASE3","title":"Administration of Prothrombin Complex Concentrate vs. Standard Transfusion During/After Heart Transplantation","status":"TERMINATED","sponsor":"University of Maryland, Baltimore","startDate":"2018-07-11","conditions":"Heart Disease End Stage, Heart Failure，Congestive","enrollment":14},{"nctId":"NCT05789537","phase":"PHASE2","title":"A Study of SerpinPC in Participants with Hemophilia B (HemB) with Inhibitors","status":"TERMINATED","sponsor":"ApcinteX Ltd","startDate":"2023-07-28","conditions":"Hemophilia B with Inhibitor, Hemophilia B","enrollment":3},{"nctId":"NCT05789524","phase":"PHASE2","title":"The Efficacy and Safety of SerpinPC in Participants with Severe Hemophilia a or Moderately Severe to Severe Hemophilia B","status":"TERMINATED","sponsor":"ApcinteX Ltd","startDate":"2023-07-06","conditions":"Hemophilia a, Hemophilia B","enrollment":60},{"nctId":"NCT05630651","phase":"NA","title":"The Efficacy and Safety of ZS801 in Chinese Hemophilia B Patients.","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2023-04-19","conditions":"Hemophilia B","enrollment":6},{"nctId":"NCT05641610","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety and Efficacy of ZS801 in Adult Hemophilia B Patients","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2022-02-16","conditions":"Hemophilia B","enrollment":21},{"nctId":"NCT05709288","phase":"PHASE1","title":"Gene Therapy for Hemophilia B Patients Aged 12-18 Years Old","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2023-03-23","conditions":"Hemophilia B","enrollment":9},{"nctId":"NCT05152732","phase":"EARLY_PHASE1","title":"Safety and Tolerability of VGB-R04 in Patients With Haemophilia B","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2021-12-28","conditions":"Hemophilia B","enrollment":3},{"nctId":"NCT04135300","phase":"NA","title":"Gene Therapy for Chinese Hemophilia B","status":"COMPLETED","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2019-10-16","conditions":"Hemophilia B","enrollment":10},{"nctId":"NCT05281718","phase":"EARLY_PHASE1","title":"Factor IX as Adjunctive Therapy to Emicizumab (EMIX)","status":"COMPLETED","sponsor":"Tulane University","startDate":"2022-08-01","conditions":"Hemophilia A","enrollment":12},{"nctId":"NCT05667805","phase":"PHASE4","title":"Coagulation in Cirrhosis","status":"RECRUITING","sponsor":"Medical University of Vienna","startDate":"2023-01-19","conditions":"Liver Cirrhosis","enrollment":400},{"nctId":"NCT06747416","phase":"PHASE2","title":"KN057 Multiple Dose Study in Patients with Hemophilia a or Hemophilia B with or Without Inhibitors","status":"NOT_YET_RECRUITING","sponsor":"Suzhou Alphamab Co., Ltd.","startDate":"2025-09-02","conditions":"Hemophilia a and B","enrollment":24},{"nctId":"NCT05010707","phase":"PHASE2","title":"Transgender Estradiol Affirming Therapy","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2021-08-02","conditions":"Transgenderism","enrollment":39},{"nctId":"NCT06627218","phase":"NA","title":"Liberal or Adhere to Recommendations for PCC Management in Major Bleeding Following Trauma","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2021-01-01","conditions":"Traumatic Bleeding","enrollment":650},{"nctId":"NCT03055611","phase":"","title":"A Study to Evaluate the Real-world Usage and Effectiveness of Elocta and Alprolix in Patients With Haemophilia A or B","status":"COMPLETED","sponsor":"Swedish Orphan Biovitrum","startDate":"2017-05-09","conditions":"Haemophilia A, Haemophilia B","enrollment":201},{"nctId":"NCT03655340","phase":"","title":"A Study to Evaluate the Real-world Effectiveness and Usage of Alprolix in Patients With Haemophilia B in France","status":"COMPLETED","sponsor":"Swedish Orphan Biovitrum","startDate":"2018-09-12","conditions":"Haemophilia B","enrollment":91},{"nctId":"NCT02937831","phase":"","title":"RIXUBIS Drug Use-Result Survey (Japan)","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2016-11-16","conditions":"Hemophilia B","enrollment":6},{"nctId":"NCT02695160","phase":"PHASE1","title":"Ascending Dose Study of Genome Editing by Zinc Finger Nuclease Therapeutic SB-FIX in Subjects With Severe Hemophilia B","status":"TERMINATED","sponsor":"Sangamo Therapeutics","startDate":"2016-11-15","conditions":"Hemophilia B","enrollment":1},{"nctId":"NCT03489291","phase":"PHASE2","title":"Dose Confirmation Trial of AAV5-hFIXco-Padua","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2018-07-24","conditions":"Hemophilia B","enrollment":3},{"nctId":"NCT02777424","phase":"PHASE4","title":"CPP Versus PFC to Correct Coagulation Disorders in Adult Neurosurgical Patients","status":"COMPLETED","sponsor":"Fondation Ophtalmologique Adolphe de Rothschild","startDate":"2016-01-21","conditions":"Intracranial Hemorrhages","enrollment":18},{"nctId":"NCT03855280","phase":"PHASE3","title":"Evaluation of a Recombinant Factor IX Product, APVO101, in Previously-Treated Pediatric Patients With Hemophilia B","status":"COMPLETED","sponsor":"Medexus Pharma, Inc.","startDate":"2020-01-16","conditions":"Hemophilia B","enrollment":21},{"nctId":"NCT04628871","phase":"","title":"Long Term Follow-up (LTFU) of Subjects Who Received SB-318, SB-913, or SB-FIX","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sangamo Therapeutics","startDate":"2020-11-03","conditions":"Hemophilia B, Mucopolysaccharidosis I, Mucopolysaccharidosis II","enrollment":13},{"nctId":"NCT05127681","phase":"NA","title":"Bone Microarchitecture in Men With Hemophilia","status":"TERMINATED","sponsor":"Hospices Civils de Lyon","startDate":"2023-08-01","conditions":"Severe Hemophilia A, Osteoporosis","enrollment":10},{"nctId":"NCT03921294","phase":"PHASE4","title":"HemLibra Prophylaxis in Patients With Hemophilic Pseudotumor","status":"TERMINATED","sponsor":"Indiana Hemophilia &Thrombosis Center, Inc.","startDate":"2019-05-15","conditions":"Haemophilic Pseudotumour","enrollment":1},{"nctId":"NCT04567511","phase":"PHASE4","title":"Hemlibra in Mild Hemophilia A","status":"RECRUITING","sponsor":"Indiana Hemophilia &Thrombosis Center, Inc.","startDate":"2022-07-25","conditions":"Factor VIII Deficiency, Congenital","enrollment":20},{"nctId":"NCT06144099","phase":"PHASE4","title":"Prothrombin Complex Concentrate vs Fresh Frozen Plasma in Goal-directed Bleeding Management in Non-cardiac Surgery","status":"UNKNOWN","sponsor":"Konkuk University Medical Center","startDate":"2024-03-01","conditions":"Prostate Cancer, Spine, Open, Hip Osteoarthritis","enrollment":154},{"nctId":"NCT01561391","phase":"PHASE4","title":"Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major Surgery","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"1998-04","conditions":"Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors","enrollment":36},{"nctId":"NCT04019015","phase":"PHASE2","title":"Prehospital Kcentra for Hemorrhagic Shock","status":"UNKNOWN","sponsor":"Oregon Health and Science University","startDate":"2021-03-15","conditions":"Trauma Injury","enrollment":166},{"nctId":"NCT05548777","phase":"","title":"Andexanet Alfa and 4F-PCC Use in Patients Hospitalised With an Anticoagulant-related Major Bleed","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-09-15","conditions":"Anticoagulant-related Major Bleed","enrollment":5480},{"nctId":"NCT06144125","phase":"PHASE4","title":"Prothrombin Complex Concentrate vs Fresh Frozen Plasma in Goal-directed Bleeding Management in Cardiac Surgery","status":"UNKNOWN","sponsor":"Konkuk University Medical Center","startDate":"2024-03-01","conditions":"Cardiac Valve Disease","enrollment":152},{"nctId":"NCT06125756","phase":"EARLY_PHASE1","title":"Safety and Efficacy Clinical Study of Severe Hemophilia B Treatment With KL001","status":"UNKNOWN","sponsor":"Affiliated Hospital of Guangdong Medical University","startDate":"2023-12-20","conditions":"Hemophilia B Without Inhibitor","enrollment":9},{"nctId":"NCT06119659","phase":"EARLY_PHASE1","title":"Safety and Efficacy Clinical Study of Severe Hemophilia B Treatment With KL001","status":"UNKNOWN","sponsor":"Zhejiang University","startDate":"2023-11-20","conditions":"Hemophilia B Without Inhibitor","enrollment":9},{"nctId":"NCT03064035","phase":"PHASE4","title":"Fixed Versus Variable Dosing of 4-factor Prothrombin Complex Concentrate for Emergent Warfarin Reversal","status":"COMPLETED","sponsor":"HealthPartners Institute","startDate":"2017-04-05","conditions":"Acute Bleeding on Long-Term Anticoagulation Therapy, Hemorrhage, Significant Bleeding in Patients With a Coagulopathy (Prolonged Thrombin Time)","enrollment":79},{"nctId":"NCT05217992","phase":"","title":"Are There Differences Between Carriers of Haemophilia A and B?","status":"COMPLETED","sponsor":"Cliniques universitaires Saint-Luc- Université Catholique de Louvain","startDate":"2021-05-25","conditions":"Hemophilia","enrollment":900},{"nctId":"NCT02803502","phase":"NA","title":"Does the Thrombin Generation Test Performed During the Pharmacokinetic Profile of the Substitutive Factor VIII Bring Benefits to the Personalized Treatment of Pediatric Patients and Adult Hemophilia A Patients Under Prophylaxis ?","status":"UNKNOWN","sponsor":"Brugmann University Hospital","startDate":"2017-01","conditions":"Hemophilia","enrollment":50},{"nctId":"NCT05164471","phase":"PHASE1, PHASE2","title":"Phase 1/2 Dose Confirmation Study of FLT180a in Hemophilia B","status":"TERMINATED","sponsor":"Spur Therapeutics","startDate":"2021-12-06","conditions":"Hemophilia B","enrollment":6},{"nctId":"NCT03641703","phase":"PHASE1, PHASE2","title":"A Long-Term Follow-Up Study of Haemophilia B Patients Who Have Undergone Gene Therapy","status":"TERMINATED","sponsor":"Spur Therapeutics","startDate":"2018-07-10","conditions":"Hemophilia B","enrollment":10},{"nctId":"NCT05889754","phase":"","title":"Reliability and Validity of the Turkish Version of the PedHAL","status":"UNKNOWN","sponsor":"Hasan Kalyoncu University","startDate":"2023-05-30","conditions":"Hemophilia, Hemophilia A, Severe, Hemophilia B","enrollment":50},{"nctId":"NCT03075670","phase":"PHASE1","title":"A Trial Comparing Nonacog Beta Pegol (N9-GP) and ALPROLIX® in Patients With Haemophilia B","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2017-03-07","conditions":"Congenital Bleeding Disorder, Haemophilia B","enrollment":15},{"nctId":"NCT04055051","phase":"","title":"ATHN 11: Liver Transplantation Outcomes Study","status":"COMPLETED","sponsor":"American Thrombosis and Hemostasis Network","startDate":"2020-06-18","conditions":"Hemophilia A and B, Liver Transplantation","enrollment":86},{"nctId":"NCT05804734","phase":"","title":"Vitamin K Antagonist Versus Direct Oral Anticoagulant Treatments in Hemophilia","status":"COMPLETED","sponsor":"Groupe Maladies hémorragiques de Bretagne","startDate":"2021-06-01","conditions":"Hemophilia A, Hemophilia B, Anticoagulant-induced Bleeding","enrollment":54},{"nctId":"NCT03533504","phase":"","title":"Web Accessible Population Pharmacokinetics Service - Hemophilia: Sources of Variability","status":"UNKNOWN","sponsor":"McMaster University","startDate":"2018-05-09","conditions":"Hemophilia A, Hemophilia B","enrollment":1000},{"nctId":"NCT02740335","phase":"PHASE3","title":"Study of Octaplex, a Four-factor Prothrombin Complex Concentrate (4F-PCC) and Beriplex® P/N (Kcentra) for the Reversal of Vitamin K Antagonist (VKA) Induced Anticoagulation in Patients Needing Urgent Surgery With Significant Bleeding Risk.","status":"COMPLETED","sponsor":"Octapharma","startDate":"2017-06-08","conditions":"Significant Bleeding Risk","enrollment":208},{"nctId":"NCT03045068","phase":"PHASE4","title":"Platelet Transfusion During Neonatal Open Heart Surgery","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2017-04-11","conditions":"Cardiac Disease, Cardiac Surgery, Cardiopulmonary Bypass","enrollment":46},{"nctId":"NCT03549871","phase":"PHASE3","title":"A Study of Fitusiran in Severe Hemophilia A and B Patients Previously Receiving Factor or Bypassing Agent Prophylaxis","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2018-07-25","conditions":"Hemophilia","enrollment":80},{"nctId":"NCT03809481","phase":"PHASE3","title":"Open-Label, Randomised, Active Controlled, Multi-Centre Phase 3 Study Safety and Efficacy of Danaparoid vs Argatroban","status":"TERMINATED","sponsor":"Aspen Global Incorporated","startDate":"2019-05-16","conditions":"Heparin-induced Thrombocytopenia","enrollment":7},{"nctId":"NCT03369444","phase":"PHASE1, PHASE2","title":"A Factor IX Gene Therapy Study (FIX-GT)","status":"TERMINATED","sponsor":"University College, London","startDate":"2017-12-05","conditions":"Hemophilia B","enrollment":10},{"nctId":"NCT03218722","phase":"PHASE3","title":"Early Administration of Prothrombin Concentrate Complex in Patients With Acute Hemorrhage Following Severe Trauma","status":"COMPLETED","sponsor":"University Hospital, Grenoble","startDate":"2017-12-29","conditions":"Shock, Hemorrhagic","enrollment":350},{"nctId":"NCT03565237","phase":"PHASE4","title":"RIXUBIS PMS India (RIXUBIS PMS)","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2018-12-07","conditions":"Hemophilia B","enrollment":25},{"nctId":"NCT02053792","phase":"PHASE3","title":"A Safety and Efficacy Extension Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2014-02-06","conditions":"Hemophilia B","enrollment":97},{"nctId":"NCT05442528","phase":"","title":"Lead-in Study of VGB-R04 Gene Therapy for Hemophilia B-- An Observational Survey Analysis Study","status":"UNKNOWN","sponsor":"Shanghai Vitalgen BioPharma Co., Ltd.","startDate":"2022-08","conditions":"Hemophilia B","enrollment":20},{"nctId":"NCT04286412","phase":"PHASE4","title":"Nonacog Alfa Prophylaxis And Treatment Of Bleeding Episodes In Previously Treated Patients With Hemophilia B","status":"COMPLETED","sponsor":"Pfizer","startDate":"2020-02-10","conditions":"Hemophilia B","enrollment":25},{"nctId":"NCT05441553","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety and Efficacy of VGB-R04 in Adult Hemophilia B Patients","status":"UNKNOWN","sponsor":"Shanghai Vitalgen BioPharma Co., Ltd.","startDate":"2022-07","conditions":"Hemophilia B","enrollment":26},{"nctId":"NCT02396342","phase":"PHASE1, PHASE2","title":"Trial of AAV5-hFIX in Severe or Moderately Severe Hemophilia B","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2015-06-10","conditions":"Hemophilia B","enrollment":10},{"nctId":"NCT03358836","phase":"","title":"Joint Health Study","status":"COMPLETED","sponsor":"Bloodworks","startDate":"2017-11-15","conditions":"Hemophilia B","enrollment":8},{"nctId":"NCT02557672","phase":"PHASE4","title":"PCC vs. FFP for Post Cardiopulmonary Bypass Coagulopathy and Bleeding","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2016-08","conditions":"Bleeding, Blood Loss, Surgical, Cardiovascular Surgical Procedures","enrollment":106},{"nctId":"NCT04394286","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Study of SHP648, an Adeno-Associated Viral Vector for Gene Transfer in Hemophilia B Subjects","status":"TERMINATED","sponsor":"Baxalta now part of Shire","startDate":"2020-05-13","conditions":"Hemophilia B","enrollment":2},{"nctId":"NCT03417245","phase":"PHASE3","title":"A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients Without Inhibitors","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2018-03-01","conditions":"Hemophilia A, Hemophilia B","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":754,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Factor IX (FIX)","genericName":"Factor IX (FIX)","companyName":"CSL Behring","companyId":"csl-behring","modality":"Biologic","firstApprovalDate":"","aiSummary":"Factor IX is a vitamin K-dependent clotting factor that replaces deficient or dysfunctional Factor IX to restore the intrinsic coagulation pathway and enable normal blood clot formation. Used for Hemophilia B (Factor IX deficiency) — prevention and treatment of bleeding episodes, Hemophilia B — perioperative management.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}